Study of the Neuroprotective Activity of a New Fumaric Acid Derivative
https://doi.org/10.33647/2074-5982-17-3-100-104
Abstract
In a narrowing beam-walking test, on the 21st day after the occlusion of the middle cerebral artery, it was found that the succinic salt of diethylaminoethanol fumaric ester (PDES), at doses of 10 and 75 mg/kg, led to a statistically signifi cant decrease in the severity of sensorimotor defi cit of the anterior and posterior contralateral limbs of male rats under the conditions of cerebral ischemia. The test substance at a dose of 10 mg/kg reduced the volume of ischemic damage to the cerebral cortex of rats by 1.5 times. In terms of neuroprotective activity, the effect of the succinic salt of diethylaminoethanol fumaric ester at a dose of 10 mg/kg is comparable to that of Citicoline at a dose of 500 mg/kg.
About the Authors
V. Ts. Bolotova
St. Petersburg State Chemical and Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Vera Ts. Bolotova*, Cand. Sci. (Pharm.), Assoc. Prof.
197376, Russian Federation, St. Petersburg, Professora Popova Str., 14, lit. A
I. A. Titovich
St. Petersburg State Chemical and Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Irina A. Titovich, Cand. Sci. (Biol.), Assoc. Prof.
197376, Russian Federation, St. Petersburg, Professora Popova Str., 14, lit. A
E. B. Shustov
St. Petersburg State Chemical and Pharmaceutical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Evgeniy B. Shustov, Dr. Sci. (Med.), Prof.
197376, Russian Federation, St. Petersburg, Professora Popova Str., 14, lit. A
References
1. Okovitij S.V., Rad’ko S.V., Shustov E.B. Sukcinatnye receptory (SUCNR1) kak perspektivnaja mishen’ farmakoterapii [Succinate receptors (SUCNR1) as a promising target for pharmacotherapy]. Chemical and Pharmaceutical J. 2015;49(9):1–7. (In Russian).
2. Titovich I.A., Sysoev Ju.I., Bolotova V.Ts., Okovitiy S.V. Nejrotropnaja aktivnost’ novogo proizvodnogo aminojetanola v uslovijah jeksperimental’noj ishemii golovnogo mozga [Neurotropic activity of a new aminoethanol derivative under conditions of experimental cerebral ischemia]. Experimental and Clinical Pharmacology. 2017;80(5):3–6. (In Russian).
3. Titovich I.A., Bolotova V.Ts. Jeksperimental’noe izuchenie antigipoksicheskoj aktivnosti novogo proizvodnogo aminojetanola [Experimental study of the antihypoxic activity of a new aminoethanol derivative]. Biomeditsina [Journal Biomed]. 2016;1:77–83. (In Russian).
4. Broeke J., Mateos Perez J.M., Pascau J. Image Processing with Image J. 2nd Ed. Packt Publ., 2015:256.
5. Longa E.Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke; a journal of cerebral circulation. 1989;20(1):84–91.
6. Schallert T., Woodlee M.T., Fleming S.M. Disentangling multiple types of recovery from brain injury. In: Krieglstein J., Klumpp S. Pharmacology of Cerebral Ischemia 2002. Stuttgart: Medpharm Scientific Publ., 2002:201–216.
Review
For citations:
Bolotova V.Ts., Titovich I.A., Shustov E.B. Study of the Neuroprotective Activity of a New Fumaric Acid Derivative. Journal Biomed. 2021;17(3):100-104. (In Russ.) https://doi.org/10.33647/2074-5982-17-3-100-104
Views:
290
Email this article 
